Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial
This workflow allows to map the survival effects of variables onto specific brain tumor locations, revealing location-dependency of prognostic variables such as tumor volume, and potentially of treatment schemes, with relevant implications in risk stratification and clinical management.
Authors
- R Henriksson
- Timothy F. Cloughesy (ORCID: https://orcid.org/0000-0002-8656-7483)
- Jingwen Yao (ORCID: https://orcid.org/0000-0002-8828-1841)
- Frank Saran (ORCID: https://orcid.org/0000-0002-3448-5064)
- Francesco Davide Sanvito (ORCID: https://orcid.org/0000-0002-9152-9684)
- R. Nishikawa
- W. P. Mason
- Brian J. Simmons (ORCID: https://orcid.org/0000-0003-0862-0055)
- Catalina Raymond (ORCID: https://orcid.org/0000-0003-2757-439X)
- Donatello Telesca (ORCID: https://orcid.org/0000-0003-0773-451X)
- Wolfgang Wick
- Lauren E. Abrey
- Benjamin M. Ellingson
- Olivier Chinot
- Josep Garcia
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- University of California, Los Angeles (US)
- Aix-Marseille Université (FR)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Princess Margaret Cancer Centre (CA)
- Acentech (United States) (US)
- Ambrx (United States) (US)
- Inhibrx (United States) (US)
- Kaiser Permanente South San Francisco Medical Center (US)
- Centrale Méditerranée (FR)
- Saitama Medical University (JP)
- Umeå University (SE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4419
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novocure
- Break Through Cancer
- Cure Brain Cancer Foundation
- Servier
- National Institutes of Health
- Genentech
- National Cancer Institute
- Congressionally Directed Medical Research Programs